Epitope
This article was originally published in The Gray Sheet
Executive Summary
Plans to file a response within the next week to an FDA Form 483 report stemming from a three-week re-inspection of manufacturing plants for the company's OraSure oral specimen collection device. The report contained 17 observations, "most" of which pertain to problems with "machinery controls, control samples and sample sizes for quality control testing," and "minor changes to procedures, to the work instructions for those procedures and to record keeping for certain procedures" at the company's Beaverton and Troutdale, Oregon facilities, Epitope says. During the original inspection for the manufacturing plants in December and January, FDA issued a 483 with 57 observations ("The Gray Sheet" Feb. 28, p. 6). In May, the company reported that FDA had sent the firm a letter outlining the "final steps required for FDA action" on the firm's OraSure premarket approval application, which was submitted in April 1991
You may also be interested in...
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.